Lepu Biopharma’s CMG901 Improves Overall Survival in Phase III Trial
Lepu Biopharma said CMG901 improved overall survival in a Phase III gastroesophageal cancer trial.
Lepu Biopharma said CMG901 improved overall survival in a Phase III gastroesophageal cancer trial.